DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 93 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Mukka Proteins Limited — Key licenses/regulatory approvals (Sub-para 12-Para B)

NSE 5 hrs ago·6 Oct 2026, 10:08 am

Mukka Proteins

Mukka Proteins Limited has informed stock exchanges that it has received key licenses and regulatory approvals. This update confirms that the company has successfully navigated necessary compliance requirements, clearing a significant procedural hurdle for its operations.

For investors, this development is a positive signal, as regulatory clearances are often prerequisites for executing expansion plans or maintaining uninterrupted business activities. It reduces uncertainty regarding the company's ability to proceed with its strategic goals.

Investors should monitor the company's future announcements to understand the specific nature of these approvals and how they might impact the company's expansion plans or operational efficiency.